CDEK
← All drugs Report issue

bms-986278

Small moleculeexperimental

Clinical trial activity

18 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
15
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Feb 7, 2018 (NCT03429933)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCN(C)C(=O)OCc1c(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)c(C)n2)nnn1C
Mol. weight
445.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07225647Phase 1Nov 7, 2025Bristol-Myers Squibb
NCT06746402Phase 1Jan 31, 2025Bristol-Myers Squibb
NCT06715683Phase 1Dec 12, 2024Bristol-Myers Squibb
NCT06723535Phase 1Dec 11, 2024Bristol-Myers Squibb
NCT06568458Phase 1Sep 19, 2024Bristol-Myers Squibb
NCT06425198Phase 1Jun 10, 2024Bristol-Myers Squibb
NCT06025578Phase 3Oct 25, 2023Bristol-Myers Squibb
NCT06003426Phase 3Sep 14, 2023Bristol-Myers Squibb
NCT05985590Phase 1Aug 18, 2023Bristol-Myers Squibb
NCT05932303Phase 1Jul 12, 2023Bristol-Myers Squibb
NCT05805904Phase 1Mar 29, 2023Bristol-Myers Squibb
NCT05684289Phase 1Jan 3, 2023Bristol-Myers Squibb
NCT04567667Phase 1Sep 30, 2020Bristol-Myers Squibb
NCT04468815Phase 1Jul 7, 2020Bristol-Myers Squibb
NCT04308681Phase 2May 14, 2020Bristol-Myers Squibb
NCT03981094Phase 1May 6, 2019Bristol-Myers Squibb
NCT03712540Phase 1Sep 6, 2018Bristol-Myers Squibb
NCT03429933Phase 1Feb 7, 2018Bristol-Myers Squibb
Showing 18 of 18 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit181832018
1 organizations
Page 1 / 1